Incyte Corporation (NASDAQ:INCY)‘s stock had its “buy” rating restated by equities researchers at Jefferies Group LLC in a research report issued to clients and investors on Friday.

INCY has been the topic of several other reports. BMO Capital Markets reaffirmed an “outperform” rating and set a $163.00 price target (down from $172.00) on shares of Incyte Corporation in a research report on Monday, September 11th. Oppenheimer Holdings, Inc. reaffirmed a “hold” rating and set a $135.00 price target on shares of Incyte Corporation in a research report on Sunday, September 10th. Credit Suisse Group AG set a $152.00 price target on Incyte Corporation and gave the stock a “buy” rating in a research report on Sunday, July 16th. Evercore ISI assumed coverage on Incyte Corporation in a research report on Wednesday, August 16th. They set an “in-line” rating and a $135.00 price target on the stock. Finally, J P Morgan Chase & Co set a $149.00 price target on Incyte Corporation and gave the stock a “buy” rating in a research report on Tuesday, August 1st. Seven analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $143.75.

Incyte Corporation (NASDAQ:INCY) opened at 113.57 on Friday. The company’s 50-day moving average price is $121.58 and its 200 day moving average price is $127.44. The stock’s market capitalization is $23.36 billion. Incyte Corporation has a 52-week low of $83.01 and a 52-week high of $153.15.

Incyte Corporation (NASDAQ:INCY) last announced its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.01). The company had revenue of $326.40 million for the quarter, compared to analyst estimates of $318.45 million. Incyte Corporation had a negative return on equity of 21.57% and a negative net margin of 11.77%. Incyte Corporation’s revenue for the quarter was up 32.5% on a year-over-year basis. During the same period in the prior year, the business posted $0.18 earnings per share. On average, equities research analysts predict that Incyte Corporation will post ($0.83) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Jefferies Group LLC Reaffirms Buy Rating for Incyte Corporation (INCY)” was reported by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/10/06/jefferies-group-llc-reaffirms-buy-rating-for-incyte-corporation-incy.html.

In other Incyte Corporation news, President Herve Hoppenot sold 70,502 shares of the firm’s stock in a transaction that occurred on Monday, September 18th. The shares were sold at an average price of $119.45, for a total value of $8,421,463.90. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Paula J. Swain sold 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $140.00, for a total transaction of $2,800,000.00. Following the completion of the transaction, the executive vice president now directly owns 55,067 shares in the company, valued at $7,709,380. The disclosure for this sale can be found here. Insiders sold a total of 109,452 shares of company stock worth $13,707,134 over the last three months. Corporate insiders own 17.70% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC purchased a new position in Incyte Corporation in the 1st quarter worth approximately $105,000. D. Scott Neal Inc. purchased a new position in Incyte Corporation in the 2nd quarter worth approximately $103,000. Cornerstone Advisors Inc. lifted its stake in Incyte Corporation by 19.6% in the 2nd quarter. Cornerstone Advisors Inc. now owns 884 shares of the biopharmaceutical company’s stock worth $111,000 after purchasing an additional 145 shares in the last quarter. FNY Partners Fund LP lifted its stake in Incyte Corporation by 4,825.0% in the 1st quarter. FNY Partners Fund LP now owns 985 shares of the biopharmaceutical company’s stock worth $131,000 after purchasing an additional 965 shares in the last quarter. Finally, Exane Asset Management purchased a new position in Incyte Corporation in the 2nd quarter worth approximately $126,000. 88.91% of the stock is currently owned by institutional investors and hedge funds.

Incyte Corporation Company Profile

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Analyst Recommendations for Incyte Corporation (NASDAQ:INCY)

Receive News & Ratings for Incyte Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corporation and related companies with MarketBeat.com's FREE daily email newsletter.